5:31 PM
 | 
Dec 12, 2011
 |  BC Extra  |  Clinical News

Celator reports CPX-351 data in relapsed AML

Celator Pharmaceuticals Inc. (Princeton, N.J.) reported data from the Phase IIb CLTR0308-205 trial of CPX-351 in 125 patients aged 18-65 years with acute myelogenous leukemia in first relapse. The product...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >